CG Oncology, Inc. (CGON) Financial Statements
CG Oncology, Inc. (CGON) reported trailing twelve-month revenue of $6.2M (up 1030.3% year on year) and net income of -$224.4M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$179.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CGONCG Oncology, Inc.Follow CGON — free
—
Price chart with a free account
- Market cap
- 5.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.01 | |
| Gross profit | — | — | -0.00 | — | |
| Research & development | 0.05 | 0.08 | 0.12 | 0.16 | |
| Operating income | -0.06 | -0.11 | -0.19 | -0.25 | |
| Pre-tax income | -0.05 | -0.09 | -0.16 | -0.22 | |
| Income tax | — | — | -0.00 | — | |
| Net income | -0.05 | -0.09 | -0.16 | -0.22 | |
| Diluted EPS ($) | -15.65 | -1.41 | -2.08 | -2.69 | |
| Diluted shares (bn) | 0.004 | 0.062 | 0.077 | — |
USD billions · SEC XBRL
CG Oncology, Inc. — questions
- What is CG Oncology, Inc.'s revenue?
- $6.2M over the twelve months to 2026-06-30, up 1030.3% year on year, from its 10-Q and 10-K filings.
- What is CG Oncology, Inc.'s net income?
- -$224.4M over the twelve months to 2026-06-30.
- What is CG Oncology, Inc.'s free cash flow?
- -$179.3M over the twelve months to 2026-06-30.
- What are CG Oncology, Inc.'s diluted earnings per share?
- $-2.69 over the twelve months to 2026-06-30.
Every figure on this page comes from CG Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.